新闻动态 News
查看更多 >>
-
2025-07-09亮点聚焦 01 AI驱动药物发现全流程的「范式迁移」:从“工具赋能”到“系统重构” 02 「虚拟→真实」的硬核闭环,数据、算法与验证的“铁人三项” 03 圆桌思辨: AI更易实现“me-better”优化?还是能催生“first-in-class”甚至“first-in-human”的原始创新? AI半月谈【第9期】 随着人工智能(AI)技术的迅猛发展,其在药物研发中的应用正逐渐从概念走向实践。AI不仅加速了早期靶点识别和高通量虚拟筛选,还在结构预测、候选药物优化等环节展现出巨大潜力。然而,如何将这些前沿技术转化为具有临床价值的实际成果,仍然是行业面临的重大挑战之一。 在此背景下,2025年7月9日(周三)20:00,《AI半月谈》09期邀请了中科计算技术西部研究院教授,图灵-达尔文实验室副主任,哲源科技联合创始人 赵宇教授,甲骨文生命科学北亚区总经理 周德标,望石智慧创始人兼CEO 周杰龙,德睿智药首席商务官 林剑博士等多位大咖,一起共同探讨AI在药物发现全流程中的最新进展...
-
2025-06-182025年6月12日至13日,2025人工智能与生物医药生态大会(AIBC2025) 在上海成功举办。大会汇聚了国内外学术界与企业界的众多知名专家学者,共同探讨人工智能(AI)技术在生物医药领域的前沿进展与应用实践。望石智慧研发副总裁黄博博士受邀出席,并就 “小分子药物的 AI 设计” 议题发表了主题演讲。 在6月13日下午的演讲中,黄博博士以 《融合实验电子密度的多模态 AI 生成模型辅助小分子药物设计》 为题,深入解析了望石智慧团队在该领域的创新思路与技术优势。他指出,药物研发过程中产生的实验电子密度数据蕴含巨大价值但尚未被充分挖掘。望石团队创新性地应用成熟的量化理论分析这些数据,深度提取其中信息。这一方法不仅能在分子生成过程中辅助标注非共价相互作用(NCI),从而更全面地理解类药分子与靶点口袋的相互作用模式,还能有效提升虚拟筛选的效率。 黄博博士在报告中着重强调了分子生成模型评估体系的重要性。针对行业普遍存在的两大痛点——“不类药分子‘刷分’现象” 和 “...
-
2025-06-132025年6月13日,北京望石智慧科技有限公司(以下简称“望石智慧”)宣布,其独立自主研发的造血祖细胞激酶1(HPK1)抑制剂SWA1211片,在上海市东方医院完成首例患者给药,正式启动针对晚期实体瘤的Ⅰ期临床研究。 SWA1211片于2025年3月同步获得中国国家药品监督管理局(NMPA)和美国食品药品监督管理局(FDA)的临床试验许可。本研究由上海市东方医院郭晔教授与复旦大学附属肿瘤医院王红霞教授共同牵头,旨在评价SWA1211片在晚期实体瘤患者中的安全性、耐受性、药代动力学特征及初步疗效。 有充分的证据表明,抑制HPK1的活性可以激动人体的免疫功能,达到治疗肿瘤的目的。SWA1211是由望石智慧公司研发团队基于该靶点的结构特点,并应用了公司自主开发的人工智能模型,快速、高效地设计开发出的一款高活性、高选择性的口服小分子HPK1抑制剂。临床前研究表明SWA1211具有同类最佳(Best-in-class)的潜质,在多个肿瘤动物模型中单药表现出显著的抗肿瘤效果,并且与PD-1抗体类药物联用展现出更强的协同抗肿瘤疗效。通过与已披...
-
2025-05-16近日,国内领先的AI制药平台研发企业北京望石智慧科技有限公司(以下简称“望石智慧”)与中国领先的创新驱动型制药企业齐鲁制药集团有限公司上海研发中心正式达成合作。此次合作将深度融合望石智慧自主研发的多模态AI 3D分子生成模型的核心技术优势,为齐鲁制药量身打造小分子药物设计的AI平台。凭借齐鲁制药在创新药研发领域的深厚经验,双方将携手加速早期药物发现进程,推动新药开发向高效、精准的方向迈进,助力创新药研发的突破与发展。 制药+AI融合,破解药物分子设计难题 药物早期研发的核心挑战之一在于设计具有高活性、高选择性和可成药性的分子结构。传统方法试错成本高,周期长。基于对传统药物研发模式的深刻反思与AI技术的理解,齐鲁制药于2024年中期正式启动了“齐鲁AI大脑平台项目”,推动齐鲁制药“AI化”。 望石智慧自主研发的多模态AI 3D分子生成大模型能够基于蛋白质空口袋或参考分子片段,快速精准生成与靶点口袋契合的结构新颖、构象合理且与口袋亲和力高的分子/分子骨架,突破传统药物...
-
2025-04-272025年4月27日,望石智慧(StoneWise)宣布,将在2025年美国癌症研究协会(AACR)年会上以壁报的形式,发布其自主研发的SWA1211(靶向HPK1)口服小分子抑制剂项目的最新研究成果。SWA1211已获得中国国家药品监督管理局(NMPA)和美国食品和药物管理局(FDA)批准,拟用于晚期实体瘤治疗。 本届AACR大会将于当地时间2025年4月25日至30日在美国芝加哥举行。 望石智慧将在此次AACR年会上展示的壁报信息如下: Poster Information 01. Topic SWA1211, a next generation HPK1 inhibitor exhibits superior anti tumor efficacy in preclinical studies 02. Location Poster Section 29 03. Session Date and Time April 29, 2025, 2:00 PM ~ 5:00 PM 04. Poster Number 5825 05. Session Title Immunomodulatory Agents and Interventions 联系我们:bd@stonewise.cn 关于AACR 美国癌症研究协会(AACR)年会是全球历史最悠久、规模最大的肿...
-
2025-04-16全球医药研发智能化浪潮下,AI技术正重塑从靶点发现到临床研究的全流程! 百世传媒重磅打造《AI智药:小分子发现与优化全链突破》线上研讨会,百世传媒-百世药学院汇聚腾迈医药、成都先导、圆壹智慧、望石智慧、碳硅智慧、智化科技、沃时科技、亿药科技、北京大学、胜普泽泰等10+家领军企业,打造年度最具实战价值的AI制药盛会!邀请“AI+制药“优质企业专家,带来最前沿的AI制药实战分享! 4月18日,让我们共同开启小分子智能研发新纪元! 会议议程 09:00AI驱动小分子药物发现:从虚拟筛选到智能优化 田川|应用科学部总监 上海腾迈联新生物技术有限公司 09:50 基于分子生成、计算化学与实验化学的苗头化合物发现整合方案 张宏波|副总裁、新药开发技术服务部负责 HitChem 10:30佰仕问问的本地AI模型构建与模型幻觉对抗策略 陈辰|总经理 百世AI 10:50AI驱动的先导化合物发现与优化 李游|测序与生物信息学总监 成都先导药物开发股份有限公司 11:30多目标优...
学术进展 Academic Progress
查看更多 >>
-
2023-10-09Mengchen Pu , Kaiyang Cheng, Xiaorong Li , Yucui Xin, Lanying Wei, Sutong Jin, Weisheng Zheng, Gongxin Peng, Qihong Tang, Jielong Zhou, Yingsheng Zhang. Volume 21P5099-51102023 DOI: https://doi.org/10.1016/j.csbj.2023.10.011 Abstract: Synthetic lethal (SL) pairs are pairs of genes whose simultaneous loss-of-function results in cell death, while a damaging mutation of either gene alone does not affect the cell’s survival. This makes SL pairs attractive targets for precision cancer therapies, as targeting the unimpaired gene of the SL pair can selectively kill cancer cells that already harbor the impaired gene. Limited by the difficulty of finding true SL pairs, especially on specific cell types, current computational approaches provide only limited insights because of overlooking the crucial aspects of cellular context dependency and mechanist...
-
2023-08-23Wenzhi Ma, Yuan Le, Xiaoxuan Shi, Qingbo Xu, Yang Xiao, Yueying Dou, Xiaoman Wang, Wenbiao Zhou, Hongbo Zhang, Bo Huang. 22 August 2023. DOI: https://doi.org/10.1038/s42004-023-00984-5 Abstract: The quest for effective virtual screening algorithms is hindered by the scarcity of training data, calling for innovative approaches. This study presents the use of experimental electron density (ED) data for improving active compound enrichment in virtual screening, supported by ED’s ability to reflect the time-averaged behavior of ligands and solvents in the binding pocket. Experimental ED-based grid matching score (ExptGMS) was developed to score compounds by measuring the degree of matching between their binding conformations and a series of multi-resolution experimental ED grids. The efficiency of ExptGMS was validated using both ...
-
2023-07-07Yucui Xin, Yingsheng Zhang 07 June 2023 DOI: https://doi.org/10.3389/fonc.2023.1168143 Abstract: Tumor cells can result from gene mutations and over-expression. Synthetic lethality (SL) offers a desirable setting where cancer cells bearing one mutated gene of an SL gene pair can be specifically targeted by disrupting the function of the other genes, while leaving wide-type normal cells unharmed. Paralogs, a set of homologous genes that have diverged from each other as a consequence of gene duplication, make the concept of SL feasible as the loss of one gene does not affect the cell’s survival. Furthermore, homozygous loss of paralogs in tumor cells is more frequent than singletons, making them ideal SL targets. Although high-throughput CRISPR-Cas9 screenings have uncovered numerous paralog-based SL pairs, the unclear mechanisms of ta...
-
2023-05-30Weisheng Zheng, Mengchen Pu, Xiaorong Li, Zhaolan Du, Sutong Jin, Xingshuai Li, Jielong Zhou, Yingsheng Zhang 30 May 2023 DOI: https://doi.org/10.1038/s41598-023-35842-w Abstract: Metastatic propagation is the leading cause of death for most cancers. Prediction and elucidation of metastatic process is crucial for the treatment of cancer. Even though somatic mutations have been linked to tumorigenesis and metastasis, it is less explored whether metastatic events can be identified through genomic mutational signatures, which are concise descriptions of the mutational processes. Here, we developed MetaWise, a Deep Neural Network (DNN) model, by applying mutational signatures as input features calculated from Whole-Exome Sequencing (WES) data of TCGA and other metastatic cohorts. This model can accurately classify metastatic tumors from pri...
-
2023-05-22Feng Zhou, Shiqiu Yin, Yi Xiao, Zaiyun Lin, Weiqiang Fu, and Yingsheng J. Zhang* May 12, 2023 DOI: https://doi.org/10.1021/acsomega.3c02294 Abstract: Drug design based on kinetic properties is growing in application. Here, we applied retrosynthesis-based pre-trained molecular representation (RPM) in machine learning (ML) to train 501 inhibitors of 55 proteins and successfully predicted the dissociation rate constant (koff) values of 38 inhibitors from an independent dataset for the N-terminal domain of heat shock protein 90α (N-HSP90). Our RPM molecular representation outperforms other pre-trained molecular representations such as GEM, MPG, and general molecular descriptors from RDKit. Furthermore, we optimized the accelerated molecular dynamics to calculate the relative retention time (RT) for the 128 inhibitors of N-HSP90 a...
-
2023-03-22Zaiyun Lin,* Shiqiu Yin, Lei Shi, Wenbiao Zhou, and Yingsheng John Zhang. March 22, 2023. DOI: https://doi.org/10.1021/acs.jcim.2c01302 Abstract: Retrosynthesis prediction, the task of identifying reactant molecules that can be usedto synthesize product molecules, is a fundamental challenge in organic chemistry and related fields.To address this challenge, we propose a novel graph-to-graph transformation model, G2GT. Themodel is built on the standard transformer structure and utilizes graph encoders and decoders.Additionally, we demonstrate the effectiveness of self-training, a data augmentation technique thatutilizes unlabeled molecular data, in improving the performance of the model. To further enhancediversity, we propose a weak ensemble method, inspired by reaction-type labels and ensemblelearning. This method incorporates beam search, nucleus sampling, and t...



